PROLONGED REMISSION AFTER TREATMENT WITH SINGLE-AGENT IBRUTINIB AS MAINTENANCE THERAPY FOLLOWING SALVAGE RADIATION THERAPY FOR REFRACTORY/RELAPSE PRIMARY CNS LYMPHOMA

被引：0
|
作者：
Du, Steven [1 ]
Bota, Daniela [2 ]
Kong, Xiao-Tang [3 ]
机构：
[1] Univ Calif Irvine, Irvine, CA USA
[2] Univ Calif Irvine, Dept Neurol, Irvine, CA USA
[3] UC Irvine Hlth, Irvine, CA USA
来源：
NEURO-ONCOLOGY | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
INNV-18
引用
收藏
页码：145 / 145
页数：1
相关论文
共 50 条
  • [21] PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL)
    Grommes, Christian
    Gavrilovic, Igor
    Kaley, Thomas
    Nolan, Craig
    Omuro, Antonio
    Wolfe, Julia
    Pentsova, Elena
    Hatzoglou, Vaios
    Mellinghoff, Ingo
    DeAngelis, Lisa
    NEURO-ONCOLOGY, 2016, 18 : 3 - 4
  • [22] Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab
    Trappe, Ralf
    Riess, Hanno
    Babel, Nina
    Hummel, Manfred
    Lehmkuhl, Hans
    Jonas, Sven
    Anagnostopoulos, Ioannis
    Papp-Vary, Matthias
    Reinke, Petra
    Hetzer, Roland
    Doerken, Bernd
    Oertel, Stephan
    TRANSPLANTATION, 2007, 83 (07) : 912 - 918
  • [23] OUTCOMES WITH SINGLE-AGENT IBRUTINIB BY PRIOR LINE OF THERAPY AND FOLLOWING IBRUTINIB DISCONTINUATION IN PATIENTS WITH CLL: ANALYSES FROM PHASE 3 STUDIES
    Hillmen, P.
    O'Brien, S. M.
    Byrd, J. C.
    Coutre, S.
    Brown, J. R.
    Barr, P. M.
    Barrientos, J. C.
    Devereux, S.
    Robak, T.
    Reddy, N. M.
    Kipps, T. J.
    Tedeschi, A.
    Cymbalista, F.
    Ghia, P.
    Chang, S.
    Ninomoto, J.
    James, D. F.
    Burger, J. A.
    HAEMATOLOGICA, 2016, 101 : 230 - 230
  • [24] Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of mCRC
    Xu, R.
    Li, Y.
    Luo, H.
    Wang, W.
    Wang, Z.
    Yuan, X.
    Ma, D.
    Wang, F. H.
    Zhang, D.
    Lin, D. R.
    Jia, J.
    Hu, X. H.
    Peng, J. W.
    Lin, Y. C.
    ANNALS OF ONCOLOGY, 2015, 26 : 43 - 43
  • [25] Treatment of indolent nonHodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone
    Armitage, JO
    Tobinai, K
    Hoelzer, D
    Rummel, MJ
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (04) : 311 - 321
  • [26] Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)
    Zhang, Janie Y.
    Briski, Robert
    Devata, Sumana
    Kaminski, Mark S.
    Phillips, Tycel
    Mayer, Tera
    Bailey, Nathanael G.
    Wilcox, Ryan A.
    BLOOD, 2016, 128 (22)
  • [27] Neurotoxicity Outcomes Following Whole Brain Radiation Therapy in Patients with Primary CNS Lymphoma
    Easwaran, T. P.
    Habib, A.
    Bachanova, V.
    Terezakis, S. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E346 - E347
  • [28] Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG
    Binkley, Michael S.
    Brady, Jessica L.
    Hajj, Carla
    Chelius, Monica
    Chau, Karen
    Balogh, Alex
    Levis, Mario
    Filippi, Andrea Riccardo
    Jones, Michael
    Ahmed, Sameera
    MacManus, Michael
    Wirth, Andrew
    Oguchi, Masahiko
    Vistisen, Anders Krog
    Andraos, Therese Youssef
    Ng, Andrea K.
    Aleman, Berthe M. P.
    Choi, Seo Hee
    Kirova, Youlia M.
    Hardy, Sara
    Reinartz, Gabriele
    Eich, Hans T.
    Bratman, Scott, V
    Constine, Louis S.
    Suh, Chang-Ok
    Dabaja, Bouthaina
    El-Galaly, Tarec C.
    Hodgson, David C.
    Ricardi, Umberto
    Yahalom, Joachim
    Mikhaeel, N. George
    Hoppe, Richard T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (03): : 522 - 529
  • [29] COMBINATION DOXORUBICIN AND ORTHOVOLTAGE RADIATION-THERAPY, SINGLE-AGENT DOXORUBICIN, AND HIGH-DOSE VINCRISTINE FOR SALVAGE THERAPY OF FERRET LYMPHOSARCOMA
    HUTSON, CA
    KOPIT, MJ
    WALDER, EJ
    JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 1992, 28 (04) : 365 - 368
  • [30] The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy
    Molica, Stefano
    Baumann, Tycho S.
    Lentini, Mirella
    Levato, Luciano
    Delgado, Julio
    Montserrat, Emili
    LEUKEMIA RESEARCH, 2020, 95
12345